This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Accelrys HEOS® Goes Live On BT Cloud Environment

BOSTON, April 9, 2013 /PRNewswire/ -- Bio-IT World --  Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, today announced that the cloud-based Accelrys HEOS® information management and collaboration workspace is now live on BT for Life Sciences R&D cloud platform. BT for Life Sciences R&D provides a secure, reliable and scalable cloud environment for HEOS users, enabling more efficient and productive networked collaboration by pharmaceutical research organizations and their partners. The latest engagement between BT and Accelrys furthers the relationship on hosting and externalization that has been in place between the companies since April 2012, while strengthening the enterprise capabilities of the Accelrys Externalized Collaboration Suite announced today at Bio-IT World. Combined with the enterprise cloud infrastructure provided by BT, the Accelrys Externalized Collaboration Suite addresses the needs of research organizations transitioning to an externalized network research environment.

To view the multimedia assets associated with this release, please click  

"With the pharmaceutical industry moving rapidly to a network research model, organizations are struggling to provide secure, real-time information exchange and IP protection across externalized networks," said Dr. Matt Hahn, senior vice president and chief technology officer, Accelrys. "Accelrys and BT recognize the need for drug discovery research organizations to collaborate effectively within a secure, reliable, global cloud infrastructure as they move to this new model."

"BT's robust Life Sciences for R&D cloud service is essential to meeting the critical business issues raised by externalized network research today," said Bas Burger, president of Global Pharmaceutical & Chemical for BT Global Services. "Combining Accelrys HEOS and other Accelrys applications for externalized research as part of BT for Life Sciences R&D enables scientists working in pharmaceutical and biotechnology companies, as well as academia and government, to collaborate effectively in a cloud environment.  The platform is designed to allow customers to comply with the industry's stringent security, regulatory and compliance requirements."

As part of the Accelrys Externalized Collaboration Suite, Accelrys HEOS is a proven Software-as-a-Service (SaaS) workspace that accelerates collaborative drug discovery. The system provides secure, real-time cloud access to data about such things as chemical registration, biological assay results, computational and visual analytics, safety assessment and pharmacokinetics data, and other project information. This material can be accessed with greatly reduced effort and IT overhead. Accelrys HEOS enables pharmaceutical and biotechnology companies, contract research organizations, academic institutions and other partnering research organizations to access critical information, share results and make informed decisions in a timely manner with all IP stored in a secure, project-specific information warehouse.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.37 -0.27%
FB $118.34 0.24%
GOOG $700.65 0.71%
TSLA $213.58 -4.00%
YHOO $37.09 3.00%


Chart of I:DJI
DOW 17,688.65 +37.39 0.21%
S&P 500 2,056.15 +5.03 0.25%
NASDAQ 4,735.0280 +9.3890 0.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs